Corvus制药 CRVS 深 沪
等待开盘 01-23 09:30:00 美东时间
25.86
+3.710
+16.75%
华盛通- 最 高26.22
- 今 开24.30
- 成交量 845.29万股
- 最 低 23.76
- 昨 收 22.15
- 总市值 19.31亿
- 52周最高 26.22
- 市盈率 静 --
- 换手率 11.32%
- 52周最低 2.54
- 委 比 -68.30%
- 总股本 7468.19万
- 历史最高 26.22
- 量 比 0.76
- 振 幅 11.11%
- 历史最低 0.607
- 每 手 1
- 风险率 2.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
美股牛股 | Corvus制药飙升166%，皮炎新药1期临床试验结果积极；RAPT大涨逾60%
Corvus制药飙升166%，皮炎新药临床试验结果积极；RAPT大涨逾60%，获葛兰素史克以22亿美元溢价收购；黄金资源大涨24%，财报强劲叠加金银价齐创新高>>
01-21 18:51
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 345.6% to $3.62 during...
01-20 20:05
Corvus Pharmaceuticals To Report Results From Cohort 4 Of Placebo-Controlled Phase 1 Clinical Trial Evaluating Soquelitinib For Atopic Dermatitis On January 20.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT) to report the
01-17 05:03
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
<p>Corvus Pharmaceuticals will host a conference call and webcast on January 20, 2026, at 8:00 am ET (5:00 am PT) to discuss results from Cohort 4 of its Phase 1 clinical trial evaluating soquelitinib for moderate to severe atopic dermatitis. The event will include a live webcast with presentation slides, accessible via the company’s investor relations website. A replay will be available for 60 days. Corvus is a biopharmaceutical company developi...
01-16 21:01
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
Corvus Pharmaceuticals announces it will release results from Cohort 4 of its Phase 1 clinical trial for soquelitinib in moderate to severe atopic dermatitis by late January 2026, canceling all prior conference appearances, including the J.P. Morgan 2026 Healthcare Conference. Soquelitinib is being tested for atopic dermatitis and is in a Phase 3 trial for relapsed/refractory PTCL. The company emphasizes the uncertainties associated with clinical...
01-05 13:30
Corvus Pharmaceuticals' Soquelitinib Shows Median Progression Free Survival Of 6.2 Months And Median Overall Survival Of 28.1 Months In T-Cell Lymphoma; Supports Ongoing Phase 3 Trial
Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapiesData supports ongoing registration Phase 3
2025-12-08 23:32
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Corvus Pharmaceuticals' leadership team will meet with investors and participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10, 2025. The chat, held at 8:30 am ET, will be webcast live and available for 90 days via the company's investor relations website. Corvus is a clinical-stage biopharmaceutical company developing ITK inhibition for cancer and immune diseases.
2025-10-31 11:30
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Corvus Pharmaceuticals announced interim results from a Phase 1b/2 trial assessing ciforadenant in combination with ipilimumab and nivolumab as a potential first-line therapy for metastatic renal cell cancer (RCC). The trial enrolled 50 patients with advanced RCC, demonstrating the triplet therapy's feasibility, tolerability, and encouraging activity. Key highlights include a 34% deep response rate and a 46% overall response rate, with the median...
2025-10-17 14:00
